Turner, Nicholas C. http://orcid.org/0000-0001-8937-0873
Laird, A. Douglas
Telli, Melinda L.
Rugo, Hope S. http://orcid.org/0000-0001-6710-4814
Mailliez, Audrey
Ettl, Johannes
Grischke, Eva-Maria
Mina, Lida A.
Balmaña, Judith http://orcid.org/0000-0002-0762-6415
Fasching, Peter A. http://orcid.org/0000-0003-4885-8471
Hurvitz, Sara A. http://orcid.org/0000-0001-7808-7191
Hopkins, Julia F.
Albacker, Lee A. http://orcid.org/0000-0002-5070-1783
Chelliserry, Jijumon
Chen, Ying
Conte, Umberto
Wardley, Andrew M. http://orcid.org/0000-0002-9639-0888
Robson, Mark E. http://orcid.org/0000-0002-3109-1692
Funding for this research was provided by:
Medivation(grant number not applicable).
Article History
Received: 24 May 2022
Accepted: 15 June 2023
First Online: 6 October 2023
Competing interests
: NCT declares no competing non-financial interests but the following competing financial interests: advisory board honoraria from AstraZeneca, Exact Sciences, Gilead Sciences, GSK, Guardant, Inivata, Lilly, Novartis, Pfizer, Relay Therapeutics, Repare Therapeutics, Roche/Genentech, and Zentalis; and research funding from AstraZeneca, Guardant Health, Inivata, Invitae, Merck Sharp & Dohme, Natera, Personalis, Pfizer, and Roche/Genentech. ADL, JC, and UC declare no competing non-financial interests but the following competing financial interests: employees of Pfizer and own stocks in Pfizer. MLT declares no competing non-financial interests but the following competing financial interests: research funding (to her institution) from AbbVie, Arvinas, Bayer, Biothera, Calithera Biosciences, EMD Serono, Genentech, GSK, Hummingbird Biosciences, Medivation, Merck, Novartis, OncoSec, Pfizer, PharmaMar, Tesaro and Vertex; and consulting/advisory fees from AbbVie, Aduro Biotech, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Gilead Sciences, GSK, G1 Therapeutics, Guardant, Immunomedics, Merck, Natera, Novartis, OncoSec, Pfizer, RefleXion, Replicate, Roche/Genentech, and Sanofi. HSR declares no competing non-financial interests but the following competing financial interests: research support to the University of California San Francisco from Astellas Pharma, AstraZeneca, Daiichi Sankyo, Gilead Sciences, GSK, Lilly, Merck & Co., Novartis, OBI Pharma, Pfizer, Pionyr Immunotherapeutics, Roche/Genentech, Sermonix Pharmaceuticals, Taiho Oncology, and Veru; travel support to academic meetings from AstraZeneca, Gilead Sciences, and Merck; and consultancy/advisory support from Blueprint, NAPO, Puma, and Scorpion Therapeutics. AM declares no competing non-financial interests but the following competing financial interests: honoraria from Pfizer, and travel/accommodation support from AstraZeneca and Pierre Fabre. JE declares no competing non-financial interests but the following competing financial interests: consulting fees from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, Roche, and Tesaro; contracted research from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Odonate, Pfizer, Roche, and Seattle Genetics; and travel support from AstraZeneca, Celgene, Daiichi Sankyo, Lilly, Novartis, Pfizer, and Tesaro. E-MG and LAM have nothing to disclose. JB declares no competing non-financial interests but the following competing financial interests: consultant/advisory board member for AstraZeneca and Pfizer; and submitted a European patent request (EP17382884.9). PAF declares no competing non-financial interests but the following competing financial interests: commercial research grants from Novartis to his institution; speakers bureau honoraria from Amgen, Celgene, Daiichi Sankyo, Novartis, Pfizer, Puma, Roche, and Teva; and consultant/advisory board member for Celgene, Daiichi Sankyo, Novartis, Pfizer, Puma, Roche, and Teva. SAH declares the following non-financial interests: unpaid TRIO-US Chief Medical Officer (until Jan 2023), unpaid consultant/steering committee member for Arvinas, AstraZeneca, Celcuity, Cyomx, Daiichi Sankyo, Dantari, Gilead Sciences, Greenwich Life Sciences, Immunomedics, Lilly, MacroGenics, Novartis, Orum, Pieris Pharmaceuticals, Puma Biotechnology, Roche/Genentech, Sanofi, Seattle Genetics/SeaGen, Zymeworks; and the following competing financial interests: contracted research support (which may include editorial assistance) from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, BioMarin, Cascadian Therapeutics, Celcuity, Cyomx, Daiichi Sankyo, Dantari, Dignitana, G1 Therapeutics, Gilead Sciences, Greenwich Life Sciences, GSK, Immunomedics, Lilly, MacroGenics, Merrimack, Novartis, OBI Pharma, Orinove, Orum, Pfizer, Phoenix Molecular Design, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Roche/Genentech, Sanofi, Seattle Genetics/SeaGen, and Zymeworks. JFH was an employee of Foundation Medicine, Inc. and a stockholder of Roche Holding AG when the study was carried out. LAA declares no competing non-financial interests but the following competing financial interests: employee of Foundation Medicine, Inc. and owns stocks in Roche Holdings AG. YC declares no competing non-financial interests but the following competing financial interests: contractor at Pfizer (until 2021) at the time the work was performed. AMW declares no competing non-financial interests but the following competing financial interests (at the time of the study): consultancy fees from ACCORD, Amgen, AstraZeneca, Athenex, Daiichi Sankyo, Lilly, MSD, NAPP, Novartis, Pfizer, Pierre Fabre, Roche, and Takeda; reimbursement from Amgen, Daiichi Sankyo, and Roche; speaker fees from AstraZeneca, Lilly, Novartis, Pfizer, and Roche; and research funding from Lilly, Novartis, Pfizer, and Roche. He was NCRI Breast Research Group early breast cancer systemic anti-cancer therapy lead 2014–21, ACP strategy director 2018–21, and a member of NHSE Clinical reference group for systemic anti-cancer therapy 2013–21 and clinical advisor to NICE for same period (all unremunerated). He left the NHS in January 2021 and worked for AstraZeneca until March 2022, when he left to concentrate fulltime on Outreach Research & Innovation Group (a company he founded to improve access to clinical trials for cancer patients). He has given talks for Roche and Seagen separately through Andrew Wardley Limited. MER declares no competing non-financial interests but the following competing financial interests: research funding from AstraZeneca and Pfizer; past research funding from AbbVie, Medivation, and Tesaro (at the time the work was performed); travel, accommodation, and expenses from AstraZeneca and other transfer of value from AstraZeneca and Pfizer.